Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
ZyCoV-D as a two-dose vaccine receives EUA from DCGI26-04-2022
26-04-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release dated April 25, 2022 titled Zydus announces publication of 'DREAM-ND' and 'DREAM-D' Phase 3 trials of Desidustat in 'American Journal of Nephrology'25-04-2022
Zydus Lifesciences Ltd - 532321 - Zydus Lifesciences Ltd reply to clarification sought by the exchange
The Exchange has sought clarification from Zydus Lifesciences Ltd with respect to news article appearing on https://www.business-standard.com dated April 15, 2022 (Link: https://www.business-standard.com/article/companies/sec-approves-two-dose-regimen-of-zydus-covid-19-vaccine-zycov-d-122041500020_1.html) titled "SEC approves two-dose regimen of Zydus Covid-19 vaccine ZyCoV-D".Zydus Lifesciences Ltd response is enclosed.19-04-2022
Zydus Lifesciences Ltd - 532321 - Clarification sought from Zydus Lifesciences Ltd
The Exchange has sought clarification from Zydus Lifesciences Ltd with respect to news article appearing on https://www.business-standard.com dated April 15, 2022 (Link: https://www.business-standard.com/article/companies/sec-approves-two-dose-regimen-of-zydus-covid-19-vaccine-zycov-d-122041500020_1.html) titled "SEC approves two-dose regimen of Zydus Covid-19 vaccine ZyCoV-D".The reply is awaited.18-04-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release dated April 18, 2022 titled 'Zydus Lifesciences receives final approval from USFDA for Cyanocobalamin Injection'.18-04-2022
Domestic branded generic formulations market can grow at 10-12%: Industry
Cadila Healthcare Chairman Pankaj Patel said the market can grow when there is overall growth15-04-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release dated April 13, 2022 titled 'Zydus to supply Sagent's Caffeine Citrate Oral Solution from Jarod, post USFDA's PAS Approval'13-04-2022
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate / issue of duplicate share certificate under regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201512-04-2022
Zydus Lifesciences Ltd - 532321 - Certificate Under Regulation 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Certificate under Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended on March 31, 202212-04-2022
Zydus Lifesciences Ltd - 532321 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayZydus Lifesciences Ltd 2CINL24230GJ1995PLC025878 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Dhaval N Soni Designation: Company Secretary EmailId: dhavalsoni@zyduslife.com Name of the Chief Financial Officer: Nitin D Parekh Designation: Chief Financial Officer EmailId: nitinparekh@zyduslife.com Date: 09/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.09-04-2022